JP2007517498A - 骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用 - Google Patents

骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用 Download PDF

Info

Publication number
JP2007517498A
JP2007517498A JP2006531018A JP2006531018A JP2007517498A JP 2007517498 A JP2007517498 A JP 2007517498A JP 2006531018 A JP2006531018 A JP 2006531018A JP 2006531018 A JP2006531018 A JP 2006531018A JP 2007517498 A JP2007517498 A JP 2007517498A
Authority
JP
Japan
Prior art keywords
bmp2a
nucleotides
oligonucleotide
gene
sirna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006531018A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517498A5 (https=
Inventor
フェインステイン、エレナ
メット、イゴー
ゴロディン、スベトラナ
シュトゥトマン、マイケル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Quark Pharmaceuticals Inc
Original Assignee
Astellas Pharma Inc
Quark Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc, Quark Pharmaceuticals Inc filed Critical Astellas Pharma Inc
Publication of JP2007517498A publication Critical patent/JP2007517498A/ja
Publication of JP2007517498A5 publication Critical patent/JP2007517498A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2006531018A 2003-10-07 2004-10-06 骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用 Withdrawn JP2007517498A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50927903P 2003-10-07 2003-10-07
PCT/IL2004/000924 WO2005041857A2 (en) 2003-10-07 2004-10-06 Bone morphogenetic protein (bmp) 2a and uses thereof

Publications (2)

Publication Number Publication Date
JP2007517498A true JP2007517498A (ja) 2007-07-05
JP2007517498A5 JP2007517498A5 (https=) 2007-11-22

Family

ID=34549195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006531018A Withdrawn JP2007517498A (ja) 2003-10-07 2004-10-06 骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用

Country Status (5)

Country Link
US (1) US20080249038A1 (https=)
EP (1) EP1670425A4 (https=)
JP (1) JP2007517498A (https=)
CA (1) CA2541852A1 (https=)
WO (1) WO2005041857A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002418A (es) * 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
JP2010539932A (ja) * 2007-09-28 2010-12-24 ストライカー コーポレイション 骨形成タンパク質に対する中和抗体を検出するための方法
AU2008306455C1 (en) 2007-10-03 2014-04-17 Quark Pharmaceuticals, Inc. Novel siRNA structures
EP2861620A2 (en) * 2012-06-14 2015-04-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
CN106282241A (zh) * 2016-08-05 2017-01-04 无锡市第二人民医院 通过CRISPR/Cas9得到敲除bmp2a基因的斑马鱼的方法
WO2018115879A1 (en) 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
IL251949A0 (en) 2017-04-26 2017-07-31 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct Small organic molecules for use in the treatment of neuro-inflammatory diseases
CN118001293B (zh) * 2023-12-12 2025-02-18 中国科学技术大学 一种治疗衰老相关认知功能障碍的药物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168050A (en) * 1990-05-24 1992-12-01 Genentech, Inc. Mammalian expression of the bone morphogenetic protein-2b using bmp2a/bmp2b fusion
DK0716610T3 (da) * 1993-08-26 2006-09-04 Genetics Inst Llc Humane knogle-morfogenetiske proteiner til anvendelse ved neural regenerering
EP0890639A3 (en) * 1997-07-09 2001-10-10 Gesellschaft für biotechnologische Forschung mbH (GBF) BMP2-induced cDNA and its use
JP2002525081A (ja) * 1998-08-27 2002-08-13 クォーク・バイオテク・インコーポレーテッド 低酸素により調節される遺伝子転写に特徴的な配列
WO2002081628A2 (en) * 2001-04-05 2002-10-17 Ribozyme Pharmaceuticals, Incorporated Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20040259247A1 (en) * 2000-12-01 2004-12-23 Thomas Tuschl Rna interference mediating small rna molecules
US20040115201A1 (en) * 2002-09-25 2004-06-17 Paz Einat Mitotic kinesin-like protein-1, MKLP1, and uses thereof

Also Published As

Publication number Publication date
US20080249038A1 (en) 2008-10-09
WO2005041857A2 (en) 2005-05-12
WO2005041857A3 (en) 2007-07-26
EP1670425A4 (en) 2008-04-16
EP1670425A2 (en) 2006-06-21
CA2541852A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
JP4468989B2 (ja) Ｒｔｐ８０１阻害剤の治療への使用
US20090214575A1 (en) Annexin II and uses thereof
US20160340674A1 (en) Compositions and Methods to Inhibit EZH2 for the Treatment of Cardiovascular Diseases
EP2268296A1 (en) Compositions and method for the diagnosis, prevention and treament of alzeimer's disease
US7968524B2 (en) Methods of enhancing long term memory formation by inhibition of Gpr12
JP2007517498A (ja) 骨形態形成タンパク質（ｂｍｐ）２ａ及びその使用
US20140093494A1 (en) Alpha synuclein toxicity
US20170002358A1 (en) Methods and pharmaceutical compositions for the treatment of heart failure
CN103957937B (zh) 用于治疗阿尔茨海默病的化合物
EP3258272B1 (en) Screening method for pain-relieving substances, and pharmaceutical composition for prevention or treatment of pain
WO2009138988A1 (en) Compositions for modulating the activity of cytoplasmic dynein and methods of using same
CA2516364A1 (en) Method of modulation
US20110301242A1 (en) Inhibitors of Cathepsin S for Prevention or Treatment of Obesity-Associated Disorders
KR101121987B1 (ko) 파골세포 골흡수 억제 ｓｉＲＮＡ 발현 벡터 및 이를 이용한 유전자 치료제
JP2005531522A (ja) 疼痛におけるｍｏｂ−５の使用
JP7325075B2 (ja) フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法
US20090029456A1 (en) STR50 and uses thereof
MXPA05005022A (es) Metodos y composiciones para tratar trastornos neurologicos.
WO2025199495A1 (en) Compositions and methods for treatment and prevention of alzheimer's disease
AU2015337859B2 (en) Use of therapeutic agents
US20130190240A1 (en) Tumor growth controlling method targeting galactosylceramide expression factor-1
KR20210114661A (ko) VEGFR-3 발현 조절을 통한 mTOR 관련 질환의 예방 또는 치료 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071005

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080425

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090814